The rate of patients that achieved an HbA1c < 7.0% without developing clinically significant or severe hypoglycemia events at week 52 were significantly higher in patients receiving insulin icodec rather than the control (41% vs. 32%; estimated odds ratio = 1.47; 95%CI: 1.13 to 1.92). This evidence concerns the gene INS and Hypoglycemia.